ESMO announces Tumour-Agnostic Classifier and Screener in Annals of Oncology

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“ESMO is pleased to announce the publication of the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S) in Annals of Oncology. This is a set of minimum requirements to screen and assess the tumour-agnostic potential of Cancer Therapies at the end of early phase trials.

The ETAC-S framework is the result of the collective effort by the ESMO Precision Medicine Working Group (PMWG) and a multidisciplinary team of international experts, aiming to optimise the drug development process with a standardised framework useful for regulatory assessment to expedite access to effective therapies.”

“ESMO Releases a New Framework to Assess the Tumour-Agnostic Potential of Cancer Therapies”

Read further.
Source: ESMO/LinkedIn

The European Society for Medical Oncology (ESMO) represents over 35,000 oncology professionals across 172 countries and is a key resource for oncology education and information. ESMO’s primary mission is to enhance the quality of cancer care, spanning prevention, diagnosis, palliative care, and patient follow-up.

It focuses on educating doctors, cancer patients, and the general public about best practices and the latest advancements in oncology, and advocates for equal access to optimal cancer care for all patients.